NeuBase Therapeutics, Inc.
Company Snapshot: NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc., a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
- Feb 11 2021 NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021
- Jan 28 2021 NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics
- Jan 11 2021 NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
- Dec 23 2020 NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020